Our work identifies new and potentially clinically actionable sensitivities in ovarian and breast cancers through combination of PRMT5 inhibitors with clinically approved drugs and as a single agent in PARP inhibitor–resistant cancers. The gene discussed is PRMT5; the disease is breast cancer.